Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

12.07.17	Amgen Says FDA Approves SBLA For BLINCYTO To Include Overall Survival (RTTNews)
12.07.17	FDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children (PR Newswire)
11.07.17	Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket (PR Newswire)
30.06.17	CARA In Pain, ALKS Enlightened, FDA Expands Approved Use Of AMGN's Vectibix (RTTNews)
29.06.17	FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer (PR Newswire)
29.06.17	Biotech Stocks Facing FDA Decision In July (RTTNews)
23.06.17	Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis (PR Newswire)
21.06.17	Amgen To Present New Data At 22nd Congress of the European Hematology Association (PR Newswire)
21.06.17	Novartis Says EMA Accepts MAA For AMG 334 For Prevention Of Migraine (RTTNews)
20.06.17	AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade (RTTNews)
19.06.17	Amgen: FDA To Review SBLA To Expand Indication For XGEVA - Quick Facts (RTTNews)
19.06.17	FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients (PR Newswire)
13.06.17	Technical Reports on Biotech Equities -- Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ (PR Newswire)
13.06.17	Amgen's Multiple Myeloma Treatment, KYPROLIS® (Carfilzomib), in Combination with Dexamethasone, Receives NICE Recommendation for Use at First Relapse (PR Newswire)
08.06.17	Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society (PR Newswire)
08.06.17	Amgen To Present At The Goldman Sachs 38th Annual Global Healthcare Conference (PR Newswire)
08.06.17	ABBV Hits A High Note, AGN Opens Wallet, TEVA's HALO Does An Encore (RTTNews)
07.06.17	Amgen: FDA Committee To Review Data Supporting BLA For ABP 215 - Quick Facts (RTTNews)
07.06.17	Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab (PR Newswire)
05.06.17	Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe (PR Newswire)
05.06.17	AMGN Finds New Use For Old Drug, NLNK Disappointed, ECYT Cuts Workforce (RTTNews)
04.06.17	Amgen Presents Data From Phase 3 XGEVA Study In Patients With Multiple Myeloma (RTTNews)
03.06.17	Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017 (PR Newswire)
02.06.17	Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge (PR Newswire)
30.05.17	Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc. (PR Newswire)
24.05.17	Mercury Insurance is Ready to Help Customers Impacted by Oklahoma Tornadoes and Storms (PR Newswire)
23.05.17	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amgen Inc. (AMGN) (PR Newswire)
22.05.17	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN (PR Newswire)
22.05.17	Amgen Posting Notable Loss In Afternoon Trading (RTTNews)
22.05.17	Amgen And UCB Announce Phase 3 Data From Active-Comparator Study Of EVENITY (RTTNews)
22.05.17	Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis (PR Newswire)
19.05.17	Amgen Announces Voting Results of Annual Meeting of Stockholders (PR Newswire)
18.05.17	Amgen Submits Biologics License Application To The FDA For Erenumab (PR Newswire)
18.05.17	Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN... (RTTNews)
17.05.17	Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio (PR Newswire)
09.05.17	Gamblit Gaming Raises New Growth Capital To Support Ongoing Skill-Based Gaming Launches (PR Newswire)
03.05.17	Biotech Stocks on Investors' Radar -- Array BioPharma, Celgene, Amgen, and Cerulean Pharma (PR Newswire)
02.05.17	Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab) (PR Newswire)
27.04.17	Amgen To Participate In The 2017 World Medical Innovation Forum™ Focused On Cardiovascular Disease (PR Newswire)
27.04.17	NICE Recommends Amgen's BLINCYTO® ▼ (Blinatumomab) for Adults With Relapsed or Refractory Philadelphia Chromosome-Negative B-Precursor Acute Lymphoblastic Leukaemia (PR Newswire)
26.04.17	Amgen Inc. Announces 6% Advance In Q1 Bottom Line (RTTNews)
26.04.17	Amgen Updates Guidance; Q1 Product Sales Down 1% YoY - Quick Facts (RTTNews)
26.04.17	Amgen Inc. Reports 6% Gain In Q1 Bottom Line (RTTNews)
26.04.17	Amgen Reports First Quarter 2017 Financial Results (PR Newswire)
26.04.17	Las Vegas Sands Reports First Quarter 2017 Results (PR Newswire)
24.04.17	Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine (PR Newswire)
18.04.17	Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES (PR Newswire)
04.04.17	Amgen Submits Applications In US, Europe To Expand Current Indication For XGEVA (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Gewinne in Frankfurt: SDAX zum Handelsende freundlich
22.11.24		EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück
22.11.24		Optimismus in Frankfurt: SDAX steigt am Nachmittag
22.11.24		Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag
22.11.24		Börse Frankfurt in Grün: TecDAX am Freitagnachmittag mit grünem Vorzeichen

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün

22.11.24

Gewinne in Frankfurt: SDAX zum Handelsende freundlich

22.11.24

EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück

22.11.24

Optimismus in Frankfurt: SDAX steigt am Nachmittag

22.11.24

Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag

22.11.24

Börse Frankfurt in Grün: TecDAX am Freitagnachmittag mit grünem Vorzeichen